Recombinant Human SGLT2 Protein，His

SGLT2 (Sodium-Glucose Cotransporter 2) is a key protein involved in glucose reabsorption in the kidneys, playing a significant role in the regulation of blood glucose levels. Research on SGLT2 has gained substantial attention due to its implications in diabetes management, particularly in Type 2 diabetes mellitus (T2DM). The discovery of SGLT2 inhibitors has transformed diabetes treatment by promoting glycemic control and offering cardiovascular and renal protective benefits. As a membrane protein, SGLT2's structure and function have been extensively studied to understand its mechanism and interactions within the renal proximal tubule. Recent advancements in recombinant protein technology enable the production of functional SGLT2 proteins for research purposes, allowing scientists to explore its biochemical properties, substrate specificity, and potential drug interactions. Understanding SGLT2 at a molecular level facilitates the development of novel therapeutic strategies aimed at enhancing glucose disposal and minimizing diabetic complications. Additionally, ongoing research focuses on exploring the role of SGLT2 beyond glucose transport, including its involvement in kidney function and potential links to metabolic pathways. Given the global rise in diabetes prevalence, elucidating the SGLT2 mechanism through recombinant protein studies holds promise for innovative treatment modalities and improving patient outcomes in the management of diabetes and associated comorbidities.